[go: up one dir, main page]

ZA949842B - Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurtoxins in particular soman - Google Patents

Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurtoxins in particular soman

Info

Publication number
ZA949842B
ZA949842B ZA949842A ZA949842A ZA949842B ZA 949842 B ZA949842 B ZA 949842B ZA 949842 A ZA949842 A ZA 949842A ZA 949842 A ZA949842 A ZA 949842A ZA 949842 B ZA949842 B ZA 949842B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
pretreatment
therapeutic system
highly toxic
neurtoxins
Prior art date
Application number
ZA949842A
Other languages
English (en)
Inventor
Thomas Hille
Walter Mueller
Bodo Asmussen
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6504684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA949842(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of ZA949842B publication Critical patent/ZA949842B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA949842A 1993-12-10 1994-12-09 Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurtoxins in particular soman ZA949842B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4342174A DE4342174C1 (de) 1993-12-10 1993-12-10 Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung

Publications (1)

Publication Number Publication Date
ZA949842B true ZA949842B (en) 1995-09-01

Family

ID=6504684

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA949842A ZA949842B (en) 1993-12-10 1994-12-09 Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurtoxins in particular soman

Country Status (19)

Country Link
US (1) US5939095A (xx)
EP (1) EP0732924B1 (xx)
JP (1) JP3739789B2 (xx)
KR (1) KR100397361B1 (xx)
AT (1) ATE433339T1 (xx)
CA (1) CA2178603C (xx)
CZ (1) CZ291057B6 (xx)
DE (2) DE4342174C1 (xx)
ES (1) ES2329426T3 (xx)
FI (1) FI122131B (xx)
HU (1) HUT74432A (xx)
IL (1) IL111942A (xx)
MY (1) MY111715A (xx)
NO (1) NO962405L (xx)
NZ (1) NZ277492A (xx)
PL (1) PL314914A1 (xx)
SK (1) SK284356B6 (xx)
WO (1) WO1995015755A1 (xx)
ZA (1) ZA949842B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
PT1140105E (pt) * 1998-12-24 2004-03-31 Janssen Pharmaceutica Nv Composicao de galantamina de libertacao controlada
AU2003228796A1 (en) * 2002-05-01 2003-11-17 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2005027905A1 (en) * 2003-09-19 2005-03-31 The Secretary Of State For Defence Pharmaceutical compositions for the treatment of organophosphate poisoning
AU2012200612B2 (en) * 2004-09-24 2014-11-20 The Government Of The United States, As Represented By The Secretary Of The Army Method of treating organophosphorus poisoning
US9132135B2 (en) 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
CA2583439C (en) * 2004-09-24 2016-05-10 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
GB0809905D0 (en) * 2008-06-02 2008-07-09 Secr Defence A Transdermal drug delivery device
CA2828884C (en) 2011-03-03 2021-04-27 Impel Neuropharma, Inc. Nasal drug delivery device
US20200163952A1 (en) * 2018-11-26 2020-05-28 Steven Hoffman Compositions and methods for treating nerve agent exposure
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
AR207805A1 (es) * 1975-02-06 1976-10-29 Alza Corp Substrato apropiado para formar apositos para la dispensacion continua de escopolamina base por via transdermica
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4952586A (en) * 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US5106831A (en) * 1987-08-13 1992-04-21 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia
US4981858A (en) * 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
DE3843239C1 (xx) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (xx) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0523150A4 (en) * 1990-04-06 1993-09-29 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
DE4115558A1 (de) * 1991-05-13 1992-11-19 Dresden Arzneimittel Prophylaktisches antidot gegen phosphororganische gifte
GB9118028D0 (en) * 1991-08-21 1991-10-09 Secr Defence Brit Improved transdrmal formulations

Also Published As

Publication number Publication date
DE4342174C1 (de) 1995-05-11
AU703692B2 (en) 1999-04-01
MY111715A (en) 2000-11-30
ATE433339T1 (de) 2009-06-15
CZ291057B6 (cs) 2002-12-11
KR100397361B1 (ko) 2004-03-24
FI962220L (fi) 1996-06-27
CZ168496A3 (en) 1996-11-13
AU1273395A (en) 1995-06-27
WO1995015755A1 (de) 1995-06-15
EP0732924B1 (de) 2009-06-10
KR960706339A (ko) 1996-12-09
PL314914A1 (en) 1996-09-30
DE59410461D1 (de) 2009-07-23
HU9601569D0 (en) 1996-08-28
FI122131B (fi) 2011-09-15
NZ277492A (en) 1998-01-26
CA2178603A1 (en) 1995-06-15
JP3739789B2 (ja) 2006-01-25
CA2178603C (en) 2005-08-09
SK284356B6 (sk) 2005-02-04
IL111942A0 (en) 1995-03-15
SK73996A3 (en) 1997-01-08
US5939095A (en) 1999-08-17
NO962405L (no) 1996-08-07
FI962220A0 (fi) 1996-05-27
IL111942A (en) 1998-02-08
NO962405D0 (no) 1996-06-07
ES2329426T3 (es) 2009-11-25
HUT74432A (en) 1996-12-30
EP0732924A1 (de) 1996-09-25
JPH09506360A (ja) 1997-06-24

Similar Documents

Publication Publication Date Title
ZA949842B (en) Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurtoxins in particular soman
IL201437A (en) Transdermal delivery systems of buprenorphine for use in treating pain
DE59808922D1 (en) Transdermales therapeutisches system
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
GR3025014T3 (en) A pharmaceutical composition for the intranasal administration of hydroxocobalamin
CA2132369A1 (en) Use for the Treatment of Mixed Skins, of an Effective Quantity of Active Substances
HU9601684D0 (en) Deuterised active agents in transdermal application
AU7784494A (en) Transdermal therapeutic system containing octyl dodecanol ascrystallization inhibitor
EP1004316A4 (en) MEDICINE AGAINST COMPLICATIONS AT DIABETIS
AU1242495A (en) Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorous cholinesterase inhibitors
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
IL110289A0 (en) Pharmaceutical compositions comprising 4'-iodo-4'- deoxydoxorubicin for treating amyloidosis
PL339736A1 (en) Method of protecting persons against contamination due to inadmissible oral taking toxic ingredients of a transdermal therapeutic system and transdermal therapeutic system containing a contaminating agent
IL114948A (en) Transdermal therapeutic system containing estradiol and process for the preparation thereof
UA23046C2 (uk) Протимікробhий засіб